Bionas cell profiling device selected by Solvay Pharmaceuticals for Target Validation
Bionas GmbH and Solvay Pharmaceuticals Research Laboratories announce that the Bionas(R) 2500 analyzing system has been recognized to be a valuable tool for target validation studies.
"It is known that angiotensin 1-8 (angiotensin II) acts via two receptors. The AT1 receptor mediates vasoconstriction upon stimulation, whereas the AT2 receptor is implicated in hypotensive effects. However, the mechanism through which angiotensin 1-7 induces its powerful hypotensive effect were unclear," explains Dr. Eric Ronken, Principal Scientist at Solvay.
On-line monitoring of endothelial cell physiology and its changes upon challenges by angiotensin 1-7 helped in delineating the mechanism of action by this peptide. "The Bionas system allows us to extend and optimize target validation studies by bringing the targets back into their physiological context", says Dr. Eric Ronken.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.